The Australian Pharmaceutical Biostatistics Group is delighted to invite members and guests to join this workshop on Implementing the estimand framework in global drug development: Application of causal inference approaches.

Date/Time:

Thursday 1st February 7.30-11pm (Sydney time)

Location:

Virtual – please contact apbgsteering@gmail.com for meeting link

Instructors:

• Mouna Akacha, Novartis Pharma AG, Basel, Switzerland
• Björn Bornkamp, Novartis Pharma AG, Basel, Switzerland
• Alex Ocampo, Novartis Pharma AG, Basel, Switzerland
• Jiawei Wei, Novartis Institutes for Biomedical Research Co., Shanghai, China

Details:

This evening short course introduces how causal inference approaches are relevant and used in the implementation of estimands framework in drug development. It includes 4 lectures:

Lecture 1 – Introduction to Estimands and Causal Inference:

1. Overview of the estimand framework and key points in ICH E9(R1)
2. Introduction to causal inference, including potential outcomes, causal effects and common assumptions;

Lecture 2 – Estimation Methods of Causal Effects Targeting at Hypothetical Estimands:

1. Introduction to common estimation methods, e.g., g-computation, IPW (Inverse probability weighting)
2. RCT examples illustrated using R code;

Lecture 3 – Principal Stratum:

1. Introduction to principal stratum estimand
2. Estimation strategies
3. Case studies in RCTs;

Lecture 4 – Conditional and Marginal Treatment Effects:

1. Introduction to conditional and marginal treatment effects
2. Appropriate estimators for conditional and marginal estimands
3. RCT examples illustrated using R code.